Laveeza Bhatti

997 total citations
20 papers, 276 citations indexed

About

Laveeza Bhatti is a scholar working on Infectious Diseases, Hepatology and Virology. According to data from OpenAlex, Laveeza Bhatti has authored 20 papers receiving a total of 276 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Infectious Diseases, 13 papers in Hepatology and 8 papers in Virology. Recurrent topics in Laveeza Bhatti's work include HIV/AIDS drug development and treatment (14 papers), Hepatitis C virus research (13 papers) and HIV Research and Treatment (8 papers). Laveeza Bhatti is often cited by papers focused on HIV/AIDS drug development and treatment (14 papers), Hepatitis C virus research (13 papers) and HIV Research and Treatment (8 papers). Laveeza Bhatti collaborates with scholars based in United States, Portugal and Spain. Laveeza Bhatti's co-authors include Neil Sidell, Matthew Bidwell Goetz, Glenn J. Wagner, Bieshia Chang, Karen Chan Osilla, Mallory D. Witt, Gery W. Ryan, E DeJesus, Mark Sulkowski and Tarek Hassanein and has published in prestigious journals such as PLoS ONE, The Journal of Infectious Diseases and Journal of Hepatology.

In The Last Decade

Laveeza Bhatti

20 papers receiving 269 citations

Peers

Laveeza Bhatti

HEPAT

EPIDE

VIROL

Paola Zuccalà Italy

Tianjun Jiang China

Gaby Knecht Germany

Almudena Torres-Cornejo Spain

Maria Aurora Carleo Italy

Janine Roney Australia

Josep M. Guardiola Spain

Elke Erne Germany

Giuseppe Bruno Italy

Ratna Sari Wijaya Indonesia

Paola Zuccalà Italy

Laveeza Bhatti

130 ×0.8

HEPAT

77 ×0.6

125 ×1.0

EPIDE

25 ×0.6

36 ×0.9

VIROL

Citations per year, relative to Laveeza Bhatti Laveeza Bhatti (= 1×) peers Paola Zuccalà

Countries citing papers authored by Laveeza Bhatti

Since Specialization

Citations

This map shows the geographic impact of Laveeza Bhatti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laveeza Bhatti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laveeza Bhatti more than expected).

Fields of papers citing papers by Laveeza Bhatti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laveeza Bhatti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laveeza Bhatti. The network helps show where Laveeza Bhatti may publish in the future.

Co-authorship network of co-authors of Laveeza Bhatti

This figure shows the co-authorship network connecting the top 25 collaborators of Laveeza Bhatti. A scholar is included among the top collaborators of Laveeza Bhatti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laveeza Bhatti. Laveeza Bhatti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wyles, David, Michael S. Saag, Rolando M. Viani, et al.. (2017). TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir. The Journal of Infectious Diseases. 215(4). 599–605. 16 indexed citations

Bhatti, Laveeza, et al.. (2015). The ASSURE study: HIV‐1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir. HIV Medicine. 17(2). 106–117. 14 indexed citations

Wohl, David A., Laveeza Bhatti, Catherine B. Small, et al.. (2014). Simplification to Abacavir/Lamivudine + Atazanavir Maintains Viral Suppression and Improves Bone and Renal Biomarkers in ASSURE, a Randomized, Open Label, Non-Inferiority Trial. PLoS ONE. 9(5). e96187–e96187. 16 indexed citations

Rodríguez‐Torres, M., Jihad Slim, Laveeza Bhatti, et al.. (2012). Peginterferon alfa-2a Plus Ribavirin for HIV-HCV Genotype 1 Coinfected Patients: A Randomized International Trial. HIV Clinical Trials. 13(3). 142–152. 49 indexed citations

Bhatti, Laveeza, et al.. (2012). Once-Daily Nevirapine XR. Journal of the International Association of Physicians in AIDS Care. 11(6). 369–373. 2 indexed citations

Wagner, Glenn J., Karen Chan Osilla, Jeffrey Garnett, et al.. (2012). Provider and Patient Correlates of Provider Decisions to Recommend HCV Treatment to HIV Co-Infected Patients. Journal of the International Association of Physicians in AIDS Care. 11(4). 245–251. 4 indexed citations

Osilla, Karen Chan, Glenn J. Wagner, Jeffrey Garnett, et al.. (2011). Patient and Provider Characteristics Associated with the Decision of HIV Coinfected Patients to Start Hepatitis C Treatment. AIDS Patient Care and STDs. 25(9). 533–538. 16 indexed citations

DeJesus, E, et al.. (2011). A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients. International Journal of Clinical Practice. 65(12). 1240–1249. 20 indexed citations

Wagner, Glenn J., Karen Chan Osilla, Jeffrey Garnett, et al.. (2011). Patient Characteristics Associated with HCV Treatment Adherence, Treatment Completion, and Sustained Virologic Response in HIV Coinfected Patients. AIDS Research and Treatment. 2011. 1–7. 8 indexed citations

10.

Baxter, John D., et al.. (2010). Susceptibility of HIV-1 to Tipranavir and Other Antiretroviral Agents in Treatment-Experienced Patients: The UTILIZE Study. Current HIV Research. 8(4). 347–354. 3 indexed citations

11.

Rodríguez‐Torres, M., Laveeza Bhatti, Richard K. Sterling, et al.. (2010). 296 PEGINTERFERON ALFA-2A (40KD) PLUS 800 OR 1000/1200 MG/DAY RBV IN G1 HIV-HCV-CO-INFECTED PATIENTS: EARLY RESPONSES TO TREATMENT AND PREDICTABILITY FOR SVR IN THE PARADIGM STUDY. Journal of Hepatology. 52. S124–S124. 1 indexed citations

12.

DeJesus, E, et al.. (2010). Nevirapine (NVP) vs ritonavir‐boosted atazanavir (ATV/r) combined with tenofovir/emtricitabine (TDF/FTC) in first‐line therapy: NEWART 48‐week data. Journal of the International AIDS Society. 13(S4). 1 indexed citations

13.

Wagner, Glenn J., Gery W. Ryan, Karen Chan Osilla, et al.. (2009). Treat Early or Wait and Monitor? A Qualitative Analysis of Provider Hepatitis C Virus Treatment Decision-Making in the Context of HIV Coinfection. AIDS Patient Care and STDs. 23(9). 715–725. 19 indexed citations

14.

Osilla, Karen Chan, Gery W. Ryan, Laveeza Bhatti, et al.. (2009). Factors That Influence an HIV Coinfected Patient's Decision to Start Hepatitis C Treatment. AIDS Patient Care and STDs. 23(12). 993–999. 21 indexed citations

15.

Weiss, Jeffrey J., Laveeza Bhatti, Douglas T. Dieterich, et al.. (2008). Hepatitis C patients’ self‐reported adherence to treatment with pegylated interferon and ribavirin. Alimentary Pharmacology & Therapeutics. 28(3). 289–293. 28 indexed citations

16.

Piliero, Peter J., et al.. (2008). Genotypic susceptibility to tipranavir of HIV-1 isolates in treatment-experienced patients. Journal of the International AIDS Society. 11(Suppl 1). P190–P190. 1 indexed citations

17.

Baxter, John D., et al.. (2008). Genotypic susceptibility to tipranavir (TPV) and darunavir (DRV) in a cohort of treatment-experienced patients (TEP). Journal of the International AIDS Society. 11(Suppl 1). P192–P192. 1 indexed citations

18.

Bhatti, Laveeza & Neil Sidell. (1994). Transcriptional regulation by retinoic acid of interleukin-2 alpha receptors in human B cells.. PubMed. 81(2). 273–9. 11 indexed citations

19.

Sidell, Neil, Bieshia Chang, & Laveeza Bhatti. (1993). Upregulation by Retinoic Acid of Interleukin-2-Receptor mRNA in Human T Lymphocytes. Cellular Immunology. 146(1). 28–37. 40 indexed citations

20.

Bhatti, Laveeza, et al.. (1992). Inhibition of B cell proliferation by antisense DNA to both α and β forms of FcϵR II. Cellular Immunology. 144(1). 117–130. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact